Navigation Links
Exagen Diagnostics Names John Alsobrook, Ph.D., Vice President and Chief Operating Officer
Date:2/17/2009

ALBUQUERQUE, N.M., Feb. 17 /PRNewswire/ -- Exagen Diagnostics, Inc., which provides proprietary molecular diagnostics testing services, genomic probes for research and analytic specific reagents to clinical laboratories and academic institutions, today announced that John Alsobrook, Ph.D., has been named vice president and chief operating officer. In his new role, Alsobrook oversees Exagen's day-to-day operations, company alliances and genomic marker discovery and development programs. He reports to Exagen Founder and Interim CEO Waneta Tuttle, Ph.D., M.B.A.

Alsobrook joined Exagen in 2006 as the company's director of genomic marker discovery, responsible for quality control and analysis of genomic data using both standard statistical approaches and Exagen's proprietary data mining engine. He played a key role in the development of the company's initial prognostic marker test that identifies the risk of recurrence in certain breast cancer patients. Alsobrook has also led the company's development of diagnostic tests for patients with gastroenterological conditions such as irritable bowel syndrome and inflammatory bowel disorder.

"John's extensive background in genomic science has provided Exagen with invaluable insight as the company develops new products and services for clinical laboratories and academic institutions," said Dinesh Patel, Ph.D., Exagen board chairman and managing director at investment firm vSpring Capital. "His experience and proven leadership skills make him a key member of the management team that will lead Exagen into the next phase of growth," Patel added.

Alsobrook has nearly 30 years of industry and faculty experience in scientific management, research and project consulting. Prior to joining Exagen, he worked as a consultant for clients including Genaissance Pharmaceuticals, Amersham Health, G.E. Healthcare and Massachusetts General Hospital. Alsobrook also worked at CuraGen Corp. as genetics supervisor for drug discovery and as senior research scientist for pharmacogenomics. From 1996-2000, Alsobrook was associate faculty scientist at Yale School of Medicine Child Study Center, where he investigated inherited psychiatric disorders. He holds B.S. degrees in biochemistry and physics from California State University Los Angeles, and both an M. Phil. and a Ph.D. from Yale University's Department of Genetics.

About Exagen Diagnostics, Inc.

Exagen Diagnostics is a CLIA-registered molecular diagnostics laboratory with a growing menu of proprietary, internally developed genomic tests. Exagen also sells genomic probes for research use and analyte specific reagents to other clinical laboratories and academic institutions. For more information, visit www.exagen.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
2. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
3. Hypertension Diagnostics Announces Fiscal Year 2007 Results
4. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
5. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
6. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
7. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
8. HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes
9. Optherion Licenses Worldwide Rights to Develop Age-Related Macular Degeneration Diagnostics Based on Chromosome 10 Genetic Variations
10. Quest Diagnostics Reports Third Quarter Results
11. ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... The American College ... to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in ... , In honor of Morris F. Collen, a pioneer in the field of medical ...
(Date:10/12/2017)... ... 2017 , ... Dr. Parsa Mohebi, the Los Angeles based ... the newly revamped Cosmetic Town journal section, featuring articles written by ... as Follicular Unit Extraction (FUE). , Dr. Mohebi says “I enjoy ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: